Radiopharm Theranostics (ADR) (RADX)
Develops targeted radiopharmaceutical diagnostics and therapies for solid tumors.
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company's joint venture with MD Anderson Cancer Center
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report)'s share price traded down 8.4% during mid-day trading on Thursday. The stock traded as low as $2.23 and last traded at $2.29. 88,911 shares changed hands during trading, a decline of 41% from the average daily volume of 151,981 shares. The stock had
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announces that it has entered into a Securities Purchase Agreement (“SPA”) with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1,281,646 American Depositary Shares (“ADSs”), representing 384,493,800 ordinary shares (with each ADS representing 300 ordinary shares) of the Company, at an offering price of US$3.16 per ADS, to raise aggregate gross proceeds of approximately US$4.1 million, before deducting the placement agent fees and other offering expenses payable by the Company.
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective).
Radiopharm Theranostics Reports Business Update
Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (the primary endpoint) in 90% of evaluable subjects (18/20)
Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI.
Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical proof-of-concept mouse xenografts demonstrated RAD 402's strong tumor targeting with minimal bone/marrow uptake and expected hepatic clearance SYDNEY, March 27, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the first patient has been dosed in its first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 being evaluated in advanced prostate cancer. The Phase 1 clinical trial (NCT07259213) is designed to study the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with advanced prostate cancer.
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study
Radiopharm Theranostics (NASDAQ: RADX) executives and clinical investigators highlighted new interim findings from the company's ongoing Phase IIb study of RAD101, a PET imaging tracer intended to help physicians evaluate suspected recurrent brain metastases after radiotherapy when MRI results are unclear. Phase IIb interim analysis: 18 of 20 patients met the primary objective During the workshop,
Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results
RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from solid tumors of different origins.
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases
Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been given an average rating of "Buy" by the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a buy rating and two have given a
RAD Increases Ownership in Radiopharm Ventures to 87.5%
SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, is pleased to announce that it has increased its ownership stake in Radiopharm Ventures, LLC, a joint venture created with The University of Texas MD Anderson Cancer Center (MDACC), from 75% to 87.5%.
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics Limited (NASDAQ: RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro.